TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30951501

Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa beverage (HSB)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Aqueous extract of H. sabdariffa (AEHS)
Number of subjects: 6
Study: 28245383

Group type: EXPERIMENTAL
Intervention: Combined treatment group (hydroxyurea plus IFN‐α)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Routine treatment group (hydroxyurea)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (30 healthy persons)
Number of subjects: 50
Study: 25398727

Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lokomat
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 24135482

Group type: EXPERIMENTAL
Intervention: Retroperitoneoscopic pyelolithotomy (RP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PNL)
Number of subjects: 44
Study: 22985776

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy plus chemotherapy (IMRT-C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 0
Study: 19571051

Group type: EXPERIMENTAL
Intervention: iBond Gluma inside (IB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (CS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: iBond Gluma inside with an extra layer (IBB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond with an extra layer (CSB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 17672073

Group type: EXPERIMENTAL
Intervention: Nimesil (200 mg/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aponil (200 mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sodium diclofenac (150 mg/day)
Number of subjects: 90
Study: 15355143

Group type: EXPERIMENTAL
Intervention: High perceptual load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Working memory load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-task coordination load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive control functions available (low cognitive load)
Number of subjects: 0
Study: 11226652

Group type: EXPERIMENTAL
Intervention: Early enteral feeding (EF)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Delayed enteral feeding (DF)
Number of subjects: 22
Study: 9845406

Group type: EXPERIMENTAL
Intervention: Somatostatin (250 microg/h)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study: 7584294

Group type: EXPERIMENTAL
Intervention: Korsakoff amnesics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 2318087

Group type: EXPERIMENTAL
Intervention: Walking on an exercise treadmill at 3.2 km/hr
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Walking on an exercise treadmill at 6.4 km/hr
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standing at rest
Number of subjects: 10
Study: 343226

Group type: EXPERIMENTAL
Intervention: Plain acetylsalicylic acid (ASA) tablet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Microencapsulated acetylsalicylic acid (ASA) tablet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control examinations (before ASA treatment)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Comparison between plain ASA and microencapsulated ASA
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ASA concentration in plasma
Number of subjects: 8
Study: 31351105

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 28605879

Group type: EXPERIMENTAL
Intervention: Rivaroxaban alone
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (Enoxaparin) alone
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Sequential therapy (Enoxaparin followed by Rivaroxaban)
Number of subjects: 287
Study: 24958738

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: HDL isolated from CHF patients (HDLNYHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HDL isolated from healthy subjects (HDLHealthy)
Number of subjects: 0
Study: 23470649

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 2 g/kg total dose (400 mg/kg per day for 5 days)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Anti-D immunoglobulin 50 μg/kg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Anti-D immunoglobulin 75 μg/kg
Number of subjects: 78
Study: 21612757

Group type: EXPERIMENTAL
Intervention: 60% ethanol lock (EL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard locks (SL)
Number of subjects: 30
Study: 19640511

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 789

Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 789
Study: 16685289

Group type: EXPERIMENTAL
Intervention: Stabilized stannous fluoride + sodium hexametaphosphate dentifrice (Crest Pro‐Health)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sodium fluoride control dentifrice
Number of subjects: 90
Study: 17007484

Group type: EXPERIMENTAL
Intervention: Seamless probation
Number of subjects: 272

Group type: COMPARATOR
Intervention: Traditional probation
Number of subjects: 272
Study: 14572428

Group type: EXPERIMENTAL
Intervention: Dietary intervention group (first year)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Control group (second year)
Number of subjects: 550
Study: 10211920

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily plus pindolol 7.5 mg daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily plus mianserin 30 mg daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg daily
Number of subjects: 31
Study: 8699500

Group type: EXPERIMENTAL
Intervention: Eight-week peer counseling and leadership training group
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study: 1860197

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg preoperatively
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo preoperatively
Number of subjects: 351
Study: 7046498

Group type: EXPERIMENTAL
Intervention: Etomidate (0.1 mg/kg) preceded by diazepam (0.1 mg/kg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Etomidate preceded by pentazocine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Etomidate preceded by diazepam
Number of subjects: 4
Study: 31976633

Group type: EXPERIMENTAL
Intervention: HAPA-intervention (sedentary behaviour)
Number of subjects: 96

Group type: COMPARATOR
Intervention: HAPA-attention control (physical activity)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 96
Study: 28682124

Group type: EXPERIMENTAL
Intervention: Physiomat® training
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (non-specific, low-intensity exercises)
Number of subjects: 99
Study: 29104320

Group type: EXPERIMENTAL
Intervention: Naltrexone adherence condition (N = 35)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Independent of naltrexone adherence condition (N = 32)
Number of subjects: 67
Study: 26365337

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 63

Group type: COMPARATOR
Intervention: NPH
Number of subjects: 63
Study: 24064695

Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg daily) plus placebo
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100 μg) plus placebo
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Vitamin D3 and calcium
Number of subjects: 159

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 159
Study: 21958551

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 283
Study: 19133045

Group type: EXPERIMENTAL
Intervention: Uterine exteriorisation
Number of subjects: 210

Group type: COMPARATOR
Intervention: Non-exteriorisation
Number of subjects: 210
Study: 16786040

Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation (NAD) for < or =6 months
Number of subjects: 560

Group type: COMPARATOR
Intervention: No neoadjuvant androgen deprivation (NAD)
Number of subjects: 560
Study: 12767658

Group type: EXPERIMENTAL
Intervention: Juice Plus (JP) and Vineyard (V) combination
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Juice Plus (JP) alone
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Juice Plus (JP) and Vineyard (V) combination and JP alone
Number of subjects: 38
Study: 10694785

Group type: COMPARATOR
Intervention: Low flavonoid diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High flavonols diet (77.3 mg/day or 110.4 mg/day)
Number of subjects: 10
Study: 9333109

Group type: EXPERIMENTAL
Intervention: Losartan (30 microg/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Angiotensin II (4 to 64 ng/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Norepinephrine (1 to 128 ng/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Single deep breath
Number of subjects: 8
Study: 8218961

Group type: EXPERIMENTAL
Intervention: Celaskon 60 mg (CK60)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Celaskon 500 mg (CK500)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3081991

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ranitidine with ethanol
Number of subjects: 10
Study: 28903787

Group type: EXPERIMENTAL
Intervention: Metacognitive methods combined with habit reversal therapy (MCT/HRT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 34
Study: 26859092

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve strain Yakult (BBG‐01)
Number of subjects: 0
Study: 24211870

Group type: EXPERIMENTAL
Intervention: Tomographic EEG neurofeedback (NF)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (EMG-BF)
Number of subjects: 25
Study: 23364913

Group type: EXPERIMENTAL
Intervention: Average-of-two walk distances after lung volume reduction surgery
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Best-of-two walk distances after lung volume reduction surgery
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Average-of-two walk distances
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Best-of-two walk distances
Number of subjects: 396
Study: 20859151

Group type: EXPERIMENTAL
Intervention: 10-microgram estradiol vaginal tablets for 52 weeks
Number of subjects: 541
Study: 18797054

Group type: EXPERIMENTAL
Intervention: Intralesional verapamil
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intralesional triamcinolone
Number of subjects: 54
Study: 15816634

Group type: EXPERIMENTAL
Intervention: Complementary administration of standardized mistletoe extract (Iscador)
Number of subjects: 0
Study: 14676074

Group type: EXPERIMENTAL
Intervention: Rofecoxib (up to 37.5 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Celecoxib (up to 300 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Aspirin (up to 500 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Naproxen sodium (500 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 36

Group type: COMPARATOR
Intervention: Aspirin-sensitive patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Aspirin-induced urticaria
Number of subjects: 36
Study: 10822094

Group type: EXPERIMENTAL
Intervention: Brief intervention training for primary care physicians and nurses
Number of subjects: 11000

Group type: EXPERIMENTAL
Intervention: Community primary care practices implementing the intervention
Number of subjects: 11000
Study: 8896479

Group type: EXPERIMENTAL
Intervention: Vasculour II Albumin pre‐impregnated prosthesis (VA group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Preclotted Vasculour II prosthesis (V group)
Number of subjects: 65
Study: 1863024

Group type: EXPERIMENTAL
Intervention: pH‐sensitive, polymer‐coated oral preparation of mesalamine 2.4 g/d
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: pH‐sensitive, polymer‐coated oral preparation of mesalamine 1.6 g/d
Number of subjects: 158

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 158
Study: 6600417

Group type: EXPERIMENTAL
Intervention: Isolated coronary artery bypass grafting (CABG)
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Patients younger than 65 years (control group)
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Patients aged 65-69 years
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Patients aged 70-74 years
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Patients aged 75 years or older
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Patients aged 65 years or older
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Coronary arteriography
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 1086
Study: 30768413

Group type: EXPERIMENTAL
Intervention: Children with depression and suicidal ideation (n=22)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Children with depression without suicidal ideation (n=57)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Healthy children (n=60)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Children with depression and SI
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Children with more television use
Number of subjects: 139
Study: 29332628

Group type: EXPERIMENTAL
Intervention: Standard risk factors (smoking)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Psychosocial factors (exhaustion, anger, anxiety, depression)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Psychological and social risk factors
Number of subjects: 570
Study: 27170028

Group type: EXPERIMENTAL
Intervention: Electronic data capture
Number of subjects: 261

Group type: COMPARATOR
Intervention: Handwritten data capture
Number of subjects: 261
Study: 25259747

Group type: EXPERIMENTAL
Intervention: Bedtime administration of antihypertensive drugs
Number of subjects: 41
Study: 22959763

Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate (17-OHPC)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone
Number of subjects: 217
Study: 19665364

Group type: EXPERIMENTAL
Intervention: Ephedrine 6 mg (group E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phenylephrine 100 microg (group P)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 18612059

Group type: EXPERIMENTAL
Intervention: Intervention group (best practice interventions with practice enhancement assistant)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 16
Study: 16079222

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion (3 kcal/min) with guar gum (4 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intraduodenal glucose infusion (3 kcal/min)
Number of subjects: 8
Study: 12417824

Group type: EXPERIMENTAL
Intervention: Stress management training (8 sessions over 10 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 33
Study: 10977378

Group type: EXPERIMENTAL
Intervention: Tailored weight loss materials
Number of subjects: 198

Group type: COMPARATOR
Intervention: Non-tailored weight loss materials (good fit)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Non-tailored weight loss materials (moderate fit)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Non-tailored weight loss materials (poor fit)
Number of subjects: 198
Study: 8803650

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg daily)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 357
Study: 1321037

Group type: EXPERIMENTAL
Intervention: Propofol (LD 2 mg kg‐1 and MD 6 mg kg‐1 h‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Etomidate (LD 0.3 mg kg‐1 and MD 0.6 mg kg‐1 h‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Midazolam (LD 0.2 mg kg‐1 and MD 0.120 mg kg‐1 h‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Methohexitone (LD 1.5 mg kg‐1 and MD 4 mg kg‐1 h‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dehydrobenzperidol (0.05-0.23 mg kg‐1) and alfentanil (LD 0.100 mg kg‐1 and MD 0.060 mg kg‐1 h‐1)
Number of subjects: 75
Study: 6547878

Group type: EXPERIMENTAL
Intervention: pindolol, 15 mg daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: hydrochlorothiazide, 50 mg daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: both drugs combined
Number of subjects: 25
Study: 30989456

Group type: EXPERIMENTAL
Intervention: 1% multi-strain probiotic
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 5% multi-strain probiotic
Number of subjects: 180

Group type: COMPARATOR
Intervention: 0% multi-strain probiotic (Control, T0)
Number of subjects: 180
Study: 28902118

Group type: EXPERIMENTAL
Intervention: Low-load group (LLG)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Moderate-load group (MLG)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-load group (HLG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 32
Study: 26628328

Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium breve BBG-001 (8.2 to 9.2 log10 CFU)
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Placebo (dilute infant formula)
Number of subjects: 1315
Study: 25354407

Group type: EXPERIMENTAL
Intervention: Podiatric treatment
Number of subjects: 205

Group type: COMPARATOR
Intervention: Standardized shoe advice
Number of subjects: 205
Study: 22177550

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 20810805

Group type: EXPERIMENTAL
Intervention: Bed net use
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Indoor residual spraying with carbamate or organophosphate insecticide
Number of subjects: 553

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 553
Study: 18991037

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% monotherapy for 12 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combination of Latanoprost 0.005% and Nipradilol 0.25% after 12 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Nipradilol 0.25% monotherapy for 12 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combination of Nipradilol 0.25% and Latanoprost 0.005% after 12 weeks
Number of subjects: 53
Study: 16105428

Group type: EXPERIMENTAL
Intervention: ETS+LR
Number of subjects: 20

Group type: COMPARATOR
Intervention: ETS‐LR
Number of subjects: 20
Study: 11815321

Group type: EXPERIMENTAL
Intervention: Biotin supplementation (300 microg/d for 14 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 12017304

Group type: EXPERIMENTAL
Intervention: Post-operative adjuvant chemotherapy including mitomycin, anthracyclines, cyclophosphamide, alkylating agents, and 5-fluorouracil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with mitomycin, 5-fluorouracil and non-specific immunomodulators (PSK and OK-432)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-operative adjuvant chemotherapy or immunochemotherapy
Number of subjects: 0
Study: 9718288

Group type: EXPERIMENTAL
Intervention: Cotinine fumarate 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotinine fumarate 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotinine fumarate 160 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7917540

Group type: EXPERIMENTAL
Intervention: vindesine (3 mg/m2/week) plus interferon-alpha 2b (6 U/m2 3 times per week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: vindesine alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: interferon-alpha 2b alone
Number of subjects: 60
Study: 2523921

Group type: EXPERIMENTAL
Intervention: 200 micrograms of salbutamol (S)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 80 micrograms of ipratropium (I)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 4 mg of cromoglycate (C)
Number of subjects: 11
Study: 909566

Group type: EXPERIMENTAL
Intervention: Anticoagulated group
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4
Study: 7034470

Group type: EXPERIMENTAL
Intervention: Timolol 10 mg twice daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Timolol 5 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 44
Study: 30483852

Group type: EXPERIMENTAL
Intervention: 24-h catheterisation protocol
Number of subjects: 79

Group type: COMPARATOR
Intervention: 48-h catheterisation protocol
Number of subjects: 79
Study: 28322662

Group type: EXPERIMENTAL
Intervention: Think Clearly About Depression online depression self‐management program
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 27310952

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 25419454

Group type: EXPERIMENTAL
Intervention: Authentic TENS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 40
Study: 22495092

Group type: EXPERIMENTAL
Intervention: CABGa (n = 6)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CABGma (n = 27)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CABGmr (n = 9)
Number of subjects: 42

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group 1 (CABGa)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group 2 (CABGma)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group 3 (CABGmr)
Number of subjects: 42
Study: 20009091

Group type: EXPERIMENTAL
Intervention: Active care management with home telemonitoring (ACM+HT group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Monthly care coordination telephone call (CC group)
Number of subjects: 150
Study: 18604680

Group type: EXPERIMENTAL
Intervention: Etoricoxib (Arcoxia)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Mefenamic acid (Ponstan)
Number of subjects: 25